See more : Interact-TV, Inc. (ITVI) Income Statement Analysis – Financial Results
Complete financial analysis of Ryvu Therapeutics S.A. (RVU.WA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ryvu Therapeutics S.A., a leading company in the Biotechnology industry within the Healthcare sector.
- Argo Living Soils Corp. (ARGO.CN) Income Statement Analysis – Financial Results
- M H Group Ltd. (9439.T) Income Statement Analysis – Financial Results
- China Minmetals Rare Earth Co., Ltd. (000831.SZ) Income Statement Analysis – Financial Results
- Tectona Ltd (TECT.TA) Income Statement Analysis – Financial Results
- Singapore Post Limited (SPSTF) Income Statement Analysis – Financial Results
Ryvu Therapeutics S.A. (RVU.WA)
About Ryvu Therapeutics S.A.
Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the area of kinases, cancer metabolism, synthetic lethality, and immuno-oncology. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 46.86M | 38.80M | 11.19M | 15.41M | 42.57M | 77.21M | 87.82M | 48.13M | 41.03M | 28.86M | 13.15M | 9.42M | 9.02M | 8.85M |
| Cost of Revenue | 17.55M | 17.41M | 13.73M | 8.76M | 92.72M | 29.65M | 25.93M | 16.87M | 14.84M | 9.70M | 6.00M | 5.73M | 2.92M | 2.93M |
| Gross Profit | 29.31M | 21.40M | -2.54M | 6.65M | -50.15M | 47.55M | 61.89M | 31.27M | 26.19M | 19.16M | 7.15M | 3.69M | 6.10M | 5.92M |
| Gross Profit Ratio | 62.54% | 55.14% | -22.69% | 43.14% | -117.82% | 61.59% | 70.48% | 64.96% | 63.84% | 66.39% | 54.35% | 39.18% | 67.67% | 66.92% |
| Research & Development | 0.00 | 25.99M | 15.02M | 13.02M | 67.63M | 53.86M | 27.09M | 17.31M | 13.00M | 13.44M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 5.56M | 4.33M | 5.47M | 22.46M | 32.35M | 17.94M | 10.54M | 8.76M | 6.16M | 4.21M | 3.66M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 4.37M | 4.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.67M | 5.56M | 4.33M | 5.47M | 4.37M | 32.35M | 17.94M | 10.54M | 8.76M | 6.16M | 4.21M | 3.66M | 0.00 | 0.00 |
| Other Expenses | 124.58M | 61.52M | 56.63M | 24.07M | -9.36M | 28.79M | 31.28M | 27.92M | 15.29M | 7.73M | 5.07M | 6.30M | 12.64M | 8.89M |
| Operating Expenses | 130.25M | 93.07M | 75.98M | 42.56M | -4.99M | 61.15M | 49.22M | 38.45M | 24.06M | 13.89M | 9.28M | 9.96M | 12.64M | 8.89M |
| Cost & Expenses | 147.81M | 110.48M | 89.70M | 51.32M | 87.73M | 90.80M | 75.14M | 55.32M | 38.89M | 23.59M | 15.28M | 15.68M | 15.56M | 11.81M |
| Interest Income | 13.83M | 1.15M | 61.44K | 218.85K | 1.04M | 1.37M | 66.49K | 283.78K | 612.76K | 18.23K | 17.24K | 202.69K | 215.66K | 7.41K |
| Interest Expense | 97.00K | 1.09M | 197.21K | 387.43K | 217.80K | 291.46K | 244.49K | 41.30K | 31.52K | 62.30K | 72.70K | 52.37K | 52.71K | 77.45K |
| Depreciation & Amortization | 10.97M | 12.90M | 12.56M | 12.36M | 7.99M | 4.99M | 5.24M | 3.62M | 3.43M | 2.35M | 208.25M | 1.66M | 1.53M | 1.40M |
| EBITDA | -81.04M | -65.21M | -65.96M | -17.87M | -35.72M | -17.26M | 17.88M | 2.48M | 5.56M | 7.61M | -211.60K | 159.29M | -3.03M | -1.68M |
| EBITDA Ratio | -172.95% | -171.12% | -578.03% | -115.76% | -62.79% | -5.07% | 17.22% | -7.47% | 15.47% | 27.17% | 1,565.96% | -50.10% | -30.93% | -18.98% |
| Operating Income | -100.95M | -71.67M | -77.87M | -35.91M | -45.14M | -13.61M | 12.64M | -1.21M | 2.07M | 5.27M | -2.13M | -6.26M | -6.54M | -2.96M |
| Operating Income Ratio | -215.42% | -184.71% | -696.08% | -232.94% | -106.04% | -17.63% | 14.39% | -2.52% | 5.05% | 18.26% | -16.18% | -66.50% | -72.54% | -33.51% |
| Total Other Income/Expenses | 8.84M | -773.00K | -363.00K | 5.08M | 1.28M | 1.36M | -3.04M | -69.19K | 747.84K | 155.20K | -198.45K | -164.45K | 2.10M | -433.42K |
| Income Before Tax | -92.11M | -79.20M | -77.42M | -30.62M | -36.03M | 8.99M | 9.60M | -1.28M | 2.82M | 5.43M | -2.37M | -6.43M | -4.61M | -3.40M |
| Income Before Tax Ratio | -196.57% | -204.09% | -692.08% | -198.62% | -84.64% | 11.64% | 10.93% | -2.67% | 6.88% | 18.80% | -17.99% | -68.24% | -51.13% | -38.41% |
| Income Tax Expense | 0.00 | 4.59M | 115.95K | 1.07M | -29.99K | 8.09M | 2.87M | -3.97M | -3.41M | -423.04K | 18.58K | -112.07K | -171.79K | -1.42M |
| Net Income | -92.11M | -83.78M | -77.53M | -31.69M | -36.00M | -106.32K | 6.41M | 2.72M | 6.27M | 5.85M | -2.39M | -6.43M | -4.44M | -1.97M |
| Net Income Ratio | -196.57% | -215.91% | -693.12% | -205.57% | -84.57% | -0.14% | 7.30% | 5.65% | 15.28% | 20.27% | -18.14% | -68.24% | -49.22% | -22.31% |
| EPS | -4.02 | -4.57 | -4.22 | -1.89 | -2.25 | -0.01 | 0.48 | 0.20 | 0.48 | 0.56 | -0.23 | -0.61 | -0.42 | -0.19 |
| EPS Diluted | -4.02 | -4.57 | -4.22 | -1.89 | -2.25 | -0.01 | 0.48 | 0.20 | 0.47 | 0.56 | -0.23 | -0.61 | -0.42 | -0.19 |
| Weighted Avg Shares Out | 22.90M | 18.33M | 18.36M | 16.77M | 15.97M | 15.47M | 13.77M | 13.44M | 13.05M | 10.46M | 10.46M | 10.46M | 10.46M | 10.46M |
| Weighted Avg Shares Out (Dil) | 22.90M | 18.33M | 18.36M | 16.77M | 15.97M | 15.52M | 13.77M | 13.74M | 13.06M | 10.46M | 10.46M | 10.46M | 10.46M | 10.46M |
Source: https://incomestatements.info
Category: Stock Reports